Glucocorticoid analogues: Potential therapeutic Alternatives for treating inflammatory muscle diseases

Endocrine, Metabolic and Immune Disorders - Drug Targets

Volumn 12, Issue 1, 2012, Pages 95-103

  Reeves, Erica K M ^c   Rayavarapu, Sree ^a,b   Damsker, Jesse M ^c   Nagaraju, Kanneboyina ^a,b,c  

^a CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^b GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^c ReveraGen BioPharma Inc   (United States)

Author keywords

Glucocorticoids; Inflammatory muscle diseases; Muscular dystrophy; Myositis

Indexed keywords

4 (2,3 DIHYDROBENZOFURAN 7 YL) 2 HYDROXY 3,3 DIMETHYL N (4 METHYL 1 OXO 2,3 BENZOXAZIN 6 YL) 2 TRIFLUOROMETHYLBUTANAMIDE; 5 ALLYL 1,2 DIHYDRO 10 METHOXY 2,2,4 TRIMETHYL 5H 1 BENZOPYRANO[3,4 F]QUINOLINE; AZATHIOPRINE; BENZYLIDENE DERIVATIVE; COMPOUND A; CREATINE KINASE; CYCLOSPORIN; DYSFERLIN; DYSTROPHIN; GLUCOCORTICOID; IMMUNOGLOBULIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INFLIXIMAB; INTERLEUKIN 12P40; KLF15 PROTEIN; LAZAROID; LGD 5552; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; METHOTREXATE; MITOGEN ACTIVATED PROTEIN KINASE; MUSCLE PROTEIN; PHYTOHEMAGGLUTININ; PLANT MEDICINAL PRODUCT; PREDNISOLONE; PREDNISONE; REDD1 PROTEIN; RITUXIMAB; RU 24858; TRANSCRIPTION FACTOR AP 1; UNCLASSIFIED DRUG; VASCULOTROPIN;

ATOPIC DERMATITIS; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL INFILTRATION; CREATINE KINASE BLOOD LEVEL; DENDRITIC CELL; DERMATOMYOSITIS; DISEASE COURSE; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENCY; DRUG TARGETING; DUCHENNE MUSCULAR DYSTROPHY; DYSFERLINOPATHY; ENDOPLASMIC RETICULUM STRESS; EOSINOPHIL; FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY; GENE MUTATION; HORMONE RESPONSIVE ELEMENT; HUMAN; HYPERGLYCEMIA; IDIOPATHIC DISEASE; IDIOPATHIC INFLAMMATORY MUSCLE DISEASE; INCLUSION BODY MYOSITIS; LIPID PEROXIDATION; MACROPHAGE; MAST CELL; MIYOSHI MYOPATHY; MUSCLE CELL; MUSCLE DEVELOPMENT; MUSCLE WEAKNESS; MUSCULAR DYSTROPHY; MYOSITIS; NEUTROPHIL; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; POLYMYOSITIS; PROMOTER REGION; PROTEIN DEGRADATION; REVIEW; SALSOLA; SALSOLA TUBERCULATIFORMIS; SARCOLEMMA; SKELETAL MUSCLE; SKIN ATROPHY; SPLEEN DISEASE; UNSPECIFIED SIDE EFFECT; UPREGULATION;

EID: 84857136938     PISSN: 18715303     EISSN: 22123873     Source Type: Journal    
DOI: 10.2174/187153012799279045     Document Type: Review

References (75)

1. Fisher, I.; Abraham, D.; Bouri, K.; Hoffman, E. P.; Muntoni, F. and Morgan, J. (2005) Prednisolone-induced changes in dystrophic skeletal muscle. FASEB J., 19, 834-836.
2. Petrof, B. J.; Shrager, J. B.; Stedman, H. H.; Kelly, A. M. and Sweeney, H. L. (1993) Dystrophin protects the sarcolemma from stresses developed during muscle contraction. Proc. Natl. Acad. Sci. USA, 90, 3710-3714.
3. Kumar, A. and Boriek, A. M. (2003) Mechanical stress activates the nuclear factor-kappaB pathway in skeletal muscle fibers: a possible role in Duchenne muscular dystrophy. FASEB J., 17, 386-396.
4. Spencer, M. J.; Montecino-Rodriguez, E.; Dorshkind, K. and Tidball, J. G. (2001) Helper (CD4(+)) and cytotoxic (CD8(+)) T cells promote the pathology of dystrophin-deficient muscle. Clin. Immunol., 98, 235-243.
5. Chen, Y. W.; Nagaraju, K.; Bakay, M.; McIntyre, O.; Rawat, R.; Shi, R. and Hoffman, E. P. (2005) Early onset of inflammation and later involvement of TGFbeta in Duchenne muscular dystrophy. Neurology, 65, 826-834.
6. McDouall, R. M.; Dunn, M. J. and Dubowitz, V. (1990) Nature of the mononuclear infiltrate and the mechanism of muscle damage in juvenile dermatomyositis and Duchenne muscular dystrophy. J. Neurol. Sci., 99, 199-217.
7. Evans, N. P.; Misyak, S. A.; Robertson, J. L.; Bassaganya-Riera, J. and Grange, R. W. (2009) Immune-mediated mechanisms potentially regulate the disease time-course of duchenne muscular dystrophy and provide targets for therapeutic intervention. PM R., 1, 755-768.
8. Hodgetts, S.; Radley, H.; Davies, M. and Grounds, M. D. (2006) Reduced necrosis of dystrophic muscle by depletion of host neutrophils, or blocking TNFalpha function with Etanercept in mdx mice. Neuromuscul. Disord., 16, 591-602.
9. Gorospe, J. R.; Tharp, M. D.; Hinckley, J.; Kornegay, J. N. and Hoffman, E. P. (1994) A role for mast cells in the progression of Duchenne muscular dystrophy? Correlations in dystrophin-deficient humans, dogs, and mice. J. Neurol. Sci., 122, 44-56.
10. Appleyard, S. T.; Dunn, M. J.; Dubowitz, V. and Rose, M. L. (1985) Increased expression of HLA ABC class I antigens by muscle fibres in Duchenne muscular dystrophy, inflammatory myopathy, and other neuromuscular disorders. Lancet, 1, 361-363.
11. McDouall, R. M.; Dunn, M. J. and Dubowitz, V. (1989) Expression of class I and class II MHC antigens in neuromuscular diseases, J. Neurol. Sci., 89, 213-226.
12. Nagaraju, K. and Lundberg, I. (2009) Inflammatory diseases of muscle and other myopathies in Kelly's Text book of Rheumatology (Firestein, G. S., Budd, R. C., Harris, J., E.D., McInnes, I. B., Ruddy, S. & Sergent, J. S., eds) pp. 1353-1380, Saunders, Elsevier, Philadelphia.
13. Nagaraju, K.; Raben, N.; Loeffler, L.; Parker, T.; Rochon, P. J.; Lee, E.; Danning, C.; Wada, R.; Thompson, C.; Bahtiyar, G.; Craft, J.; Hooft Van Huijsduijnen, R. and Plotz, P. (2000) Conditional up-regulation of MHC class I in skeletal muscle leads to self-sustaining autoimmune myositis and myositis-specific autoantibodies. Proc. Natl. Acad. Sci. USA, 97, 9209-9214.
14. Nagaraju, K.; Casciola-Rosen, L.; Lundberg, I.; Rawat, R.; Cutting, S.; Thapliyal, R.; Chang, J.; Dwivedi, S.; Mitsak, M.; Chen, Y. W.; Plotz, P.; Rosen, A.; Hoffman, E. and Raben, N. (2005) Activation of the endoplasmic reticulum stress response in autoimmune myositis: potential role in muscle fiber damage and dysfunction. Arthritis Rheum., 52, 1824-1835.
15. Henriques-Pons, A. and Nagaraju, K. (2009) Nonimmune mechanisms of muscle damage in myositis: role of the endoplasmic reticulum stress response and autophagy in the disease pathogenesis. Curr. Opin. Rheumatol., 21, 581-587.
16. Beenakker, E. A.; Fock, J. M.; Van Tol, M. J.; Maurits, N. M.; Koopman, H. M.; Brouwer, O. F. and Van der Hoeven, J. H. (2005) Intermittent prednisone therapy in Duchenne muscular dystrophy: a randomized controlled trial, Arch. Neurol., 62, 128-132.
17. Distad, B. J.; Amato, A. A. and Weiss, M. D. Inflammatory myopathies. Curr. Treat. Options Neurol., 13, 119-130.
18. Lowenberg, M.; Stahn, C.; Hommes, D. W. and Buttgereit, F. (2008) Novel insights into mechanisms of glucocorticoid action and the development of new glucocorticoid receptor ligands. Steroids, 73, 1025-1029.
19. Buttgereit, F. and Scheffold, A. (2002) Rapid glucocorticoid effects on immune cells. Steroids, 67, 529-534.
20. Buttgereit, F. (2000) Mechanisms and clinical relevance of nongenomic glucocorticoid actions. Z. Rheumatol., 59(Suppl 2), II/ 119-123.
21. Croxtall, J. D.; Choudhury, Q. and Flower, R. J. (2000) Glucocorticoids act within minutes to inhibit recruitment of signalling factors to activated EGF receptors through a receptor-dependent, transcription-independent mechanism. Br. J. Pharmacol., 130, 289-298.
22. Mendell, J. R.; Moxley, R. T.; Griggs, R. C.; Brooke, M. H.; Fenichel, G. M.; Miller, J. P.; King, W.; Signore, L.; Pandya, S.; Florence, J.; et al. (1989) Randomized, double-blind six-month trial of prednisone in Duchenne's muscular dystrophy. N. Engl. J. Med., 320, 1592-1597.
23. Manzur, A. Y.; Kuntzer, T.; Pike, M. and Swan, A. (2008) Glucocorticoid corticosteroids for Duchenne muscular dystrophy. Cochrane Database Syst. Rev., CD003725.
24. Baltgalvis, K. A.; Call, J. A.; Nikas, J. B. and Lowe, D. A. (2009) Effects of prednisolone on skeletal muscle contractility in mdx mice. Muscle Nerve., 40, 443-454.
25. Biedasek, K.; Andres, J.; Mai, K.; Adams, S.; Spuler, S.; Fielitz, J. and Spranger, J. (2011) Skeletal muscle 11beta-HSD1 controls glucocorticoid-induced proteolysis and expression of E3 ubiquitin ligases atrogin-1 and MuRF-1, PLoS One, 6, e16674.
26. Schakman, O.; Gilson, H.; Kalista, S. and Thissen, J. P. (2009) Mechanisms of muscle atrophy induced by glucocorticoids. Horm. Res., 72 Suppl 1, 36-41.
27. Shimizu, N.; Yoshikawa, N.; Ito, N.; Maruyama, T.; Suzuki, Y.; Takeda, S.; Nakae, J.; Tagata, Y.; Nishitani, S.; Takehana, K.; Sano, M.; Fukuda, K.; Suematsu, M.; Morimoto, C. and Tanaka, H. Crosstalk between glucocorticoid receptor and nutritional sensor mTOR in skeletal muscle. Cell Metab., 13, 170-182.
28. Guerron, A. D.; Rawat, R.; Sali, A.; Spurney, C. F.; Pistilli, E.; Cha, H. J.; Pandey, G. S.; Gernapudi, R.; Francia, D.; Farajian, V.; Escolar, D. M.; Bossi, L.; Becker, M.; Zerr, P.; de la Porte, S.; Gordish-Dressman, H.; Partridge, T.; Hoffman, E. P. and Nagaraju, K. (2011) Functional and molecular effects of arginine butyrate and prednisone on muscle and heart in the mdx mouse model of Duchenne Muscular Dystrophy. PLoS One, 5, e11220.
29. Schacke, H.; Docke, W. D. and Asadullah, K. (2002) Mechanisms involved in the side effects of glucocorticoids, Pharmacol. Ther., 96, 23-43.
30. Cordeiro, A. C. and Isenberg, D. A. (2006) Treatment of inflammatory myopathies, Postgrad. Med. J., 82, 417-424.
31. Coghlan, M. J.; Jacobson, P. B.; Lane, B.; Nakane, M.; Lin, C. W.; Elmore, S. W.; Kym, P. R.; Luly, J. R.; Carter, G. W.; Turner, R.; Tyree, C. M.; Hu, J.; Elgort, M.; Rosen, J. and Miner, J. N. (2003) A novel antiinflammatory maintains glucocorticoid efficacy with reduced side effects, Mol. Endocrinol., 17, 860-869.
32. Elmore, S. W.; Coghlan, M. J.; Anderson, D. D.; Pratt, J. K.; Green, B. E.; Wang, A. X.; Stashko, M. A.; Lin, C. W.; Tyree, C. M.; Miner, J. N.; Jacobson, P. B.; Wilcox, D. M. and Lane, B. C. (2001) Nonsteroidal selective glucocorticoid modulators: the effect of C-5 alkyl substitution on the transcriptional activation/repression profile of 2,5-dihydro-10-methoxy-2,2,4-trimethyl-1H-[1]benzopyrano [3,4-f]quinolines. J. Med. Chem., 44, 4481-4491.
33. Owen, H. C.; Miner, J. N.; Ahmed, S. F. Farquharson, C. (2007) The growth plate sparing effects of the selective glucocorticoid receptor modulator, AL-438, Mol. Cell Endocrinol., 264, 164-170.
34. Schacke, H.; Schottelius, A.; Docke, W. D.; Strehlke, P.; Jaroch, S.; Schmees, N.; Rehwinkel, H.; Hennekes, H. and Asadullah, K. (2004) Dissociation of transactivation from transrepression by a selective glucocorticoid receptor agonist leads to separation of therapeutic effects from side effects. Proc. Natl. Acad. Sci. USA, 101, 227-232.
35. Humphrey, E. L.; Williams, J. H.; Davie, M. W. and Marshall, M. J. (2006) Effects of dissociated glucocorticoids on OPG and RANKL in osteoblastic cells. Bone, 38, 652-661.
36. Schacke, H.; Zollner, T. M.; Docke, W. D.; Rehwinkel, H.; Jaroch, S.; Skuballa, W.; Neuhaus, R.; May, E.; Zugel, U. and Asadullah, K. (2009) Characterization of ZK 245186, a novel, selective glucocorticoid receptor agonist for the topical treatment of inflammatory skin diseases. Br. J. Pharmacol., 158, 1088-1103.
37. Miner, J. N.; Ardecky, B.; Benbatoul, K.; Griffiths, K.; Larson, C. J.; Mais, D. E.; Marschke, K.; Rosen, J.; Vajda, E.; Zhi, L. and Negro-Vilar, A. (2007) Antiinflammatory glucocorticoid receptor ligand with reduced side effects exhibits an altered protein-protein interaction profile. Proc. Natl. Acad. Sci. USA, 104, 19244-19249.
38. Lopez, F. J.; Ardecky, R. J.; Bebo, B.; Benbatoul, K.; De Grandpre, L.; Liu, S.; Leibowitz, M. D.; Marschke, K.; Rosen, J.; Rungta, D.; Viveros, H. O.; Yen, W. C.; Zhi, L.; Negro-Vilar, A. and Miner, J. N. (2008) LGD-5552, an antiinflammatory glucocorticoid receptor ligand with reduced side effects, in vivo. Endocrinology, 149, 2080-2089.
39. De Bosscher, K.; Vanden Berghe, W.; Beck, I. M.; Van Molle, W.; Hennuyer, N.; Hapgood, J.; Libert, C.; Staels, B.; Louw, A. and Haegeman, G. (2005) A fully dissociated compound of plant origin for inflammatory gene repression. Proc. Natl. Acad. Sci. USA, 102, 15827-15832.
40. Dewint, P.; Gossye, V.; De Bosscher, K.; Vanden Berghe, W.; Van Beneden, K.; Deforce, D.; Van Calenbergh, S.; Muller-Ladner, U.; Vander Cruyssen, B.; Verbruggen, G.; Haegeman, G. and Elewaut, D. (2008) A plant-derived ligand favoring monomeric glucocorticoid receptor conformation with impaired transactivation potential attenuates collagen-induced arthritis. J. Immunol., 180, 2608-2615.
41. Wust, S.; Tischner, D.; John, M.; Tuckermann, J. P.; Menzfeld, C.; Hanisch, U. K.; van den Brandt, J.; Luhder, F. and Reichardt, H. M. (2009) Therapeutic and adverse effects of a non-steroidal glucocorticoid receptor ligand in a mouse model of multiple sclerosis. PLoS One., 4, e8202.
42. Robertson, S.; Allie-Reid, F.; Vanden Berghe, W.; Visser, K.; Binder, A.; Africander, D.; Vismer, M.; De Bosscher, K.; Hapgood, J.; Haegeman, G. and Louw, A. Abrogation of glucocorticoid receptor dimerization correlates with dissociated glucocorticoid behavior of compound a. J. Biol. Chem., 285, 8061-8075.
43. Zhang, Z.; Zhang, Z. Y. and Schluesener, H. J. (2009) Compound A, a plant origin ligand of glucocorticoid receptors, increases regulatory T cells and M2 macrophages to attenuate experimental autoimmune neuritis with reduced side effects. J. Immunol., 183, 3081-3091.
44. van Loo, G.; Sze, M.; Bougarne, N.; Praet, J.; Mc Guire, C.; Ullrich, A.; Haegeman, G.; Prinz, M.; Beyaert, R. and De Bosscher, K. Antiinflammatory properties of a plant-derived nonsteroidal, dissociated glucocorticoid receptor modulator in experimental autoimmune encephalomyelitis. Mol. Endocrinol., 24, 310-322.
45. Vayssiere, B. M.; Dupont, S.; Choquart, A.; Petit, F.; Garcia, T.; Marchandeau, C.; Gronemeyer, H. and Resche-Rigon, M. (1997) Synthetic glucocorticoids that dissociate transactivation and AP-1 transrepression exhibit antiinflammatory activity in vivo, Mol. Endocrinol., 11, 1245-1255.
46. Belvisi, M. G.; Wicks, S. L.; Battram, C. H.; Bottoms, S. E.; Redford, J. E.; Woodman, P.; Brown, T. J.; Webber, S. E. and Foster, M. L. (2001) Therapeutic benefit of a dissociated glucocorticoid and the relevance of in vitro separation of transrepression from transactivation activity. J. Immunol., 166, 1975-1982.
47. Schacke, H.; Berger, M.; Rehwinkel, H. and Asadullah, K. (2007) Selective glucocorticoid receptor agonists (SEGRAs): novel ligands with an improved therapeutic index. Mol. Cell Endocrinol., 275, 109-117.
48. Chen, T. (2008) Nuclear receptor drug discovery. Curr. Opin. Chem. Biol., 12, 418-426.
49. De Bosscher, K.; Beck, I. M. and Haegeman, G. (2010) Classic glucocorticoids versus non-steroidal glucocorticoid receptor modulators: survival of the fittest regulator of the immune system?, Brain Behav. Immun., 24, 1035-1042.
50. Hall, E. D.; Braughler, J. M. and McCall, J. M. (1990) Role of oxygen radicals in stroke: effects of the 21-aminosteroids (lazaroids). A novel class of antioxidants. Prog. Clin. Biol. Res., 361, 351-362.
51. McCall, J. M.; Braughler, J. M. and Hall, E. D. (1987) A new class of compounds for stroke and trauma: effects of 21-aminosteroids on lipid peroxidation. Acta Anaesthesiol. Belg., 38, 417-420.
52. Braughler, J. M.; Chase, R. L.; Neff, G. L.; Yonkers, P. A.; Day, J. S.; Hall, E. D.; Sethy, V. H. and Lahti, R. A. (1988) A new 21- aminosteroid antioxidant lacking glucocorticoid activity stimulates adrenocorticotropin secretion and blocks arachidonic acid release from mouse pituitary tumor (AtT-20) cells. J. Pharmacol. Exp. Ther., 244, 423-427.
53. Hall, E. D.; McCall, J. M. and Means, E. D. (1994) Therapeutic potential of the lazaroids (21-aminosteroids) in acute central nervous system trauma, ischemia and subarachnoid hemorrhage. Adv. Pharmacol., 28, 221-268.
54. Spassov, A.; Gredes, T.; Gedrange, T.; Pavlovic, D.; Lupp, A. and Kunert-Keil, C. (2011) Increased oxidative stress in dystrophin deficient (mdx) mice masticatory muscles. Exp. Toxicol. Pathol., 63, 549-552.
55. Tidball, J. G. and Wehling-Henricks, M. (2007) The role of free radicals in the pathophysiology of muscular dystrophy. J. Appl. Physiol., 102, 1677-1686.
56. Ragusa, R. J.; Chow, C. K. and Porter, J. D. (1997) Oxidative stress as a potential pathogenic mechanism in an animal model of Duchenne muscular dystrophy. Neuromuscul. Disord., 7, 379-386.
57. Rodriguez, M. C. and Tarnopolsky, M. A. (2003) Patients with dystrophinopathy show evidence of increased oxidative stress. Free Radic Biol. Med., 34, 1217-1220.
58. Messina, S.; Bitto, A.; Aguennouz, M.; Minutoli, L.; Monici, M. C.; Altavilla, D.; Squadrito, F. and Vita, G. (2006) Nuclear factor kappa-B blockade reduces skeletal muscle degeneration and enhances muscle function in Mdx mice. Exp. Neurol., 198, 234-241.
59. Metzinger, L.; Passaquin, A. C.; Vernier, A.; Thiriet, N.; Warter, J. M. and Poindron, P. (1994) Lazaroids enhance skeletal myogenesis in primary cultures of dystrophin-deficient mdx mice. J. Neurol. Sci., 126, 138-145.
60. Fukuma, K.; Marubayashi, S.; Okada, K.; Yamada, K.; Kimura, A. and Dohi, K. (1999) Effect of lazaroid U-74389G and methylprednisolone on endotoxin-induced shock in mice. Surgery, 125, 421-430.
61. Marubayashi, S.; Okada, K.; Fukuma, K.; Tashiro, H.; Kitayama, T.; Hayamizu, K.; Dohi, K. and Asahara, T. (2002) Effect of lazaroids on NF-kappa B activation of Kupffer cells in liver preservation, Transplant. Proc., 34, 2662-2663.
62. Okada, K.; Marubayashi, S.; Fukuma, K.; Yamada, K. and Dohi, K. (2000) Effect of the 21-aminosteroid on nuclear factor-kappa B activation of Kupffer cells in endotoxin shock. Surgery, 127, 79-86.
63. Hsieh, H. M.; Wu, W. M. and Hu, M. L. Genistein attenuates Dgalactose-induced oxidative damage through decreased reactive oxygen species and NF-kappaB binding activity in neuronal PC12 cells. Life Sci., 88, 82-88.
64. Tunon, M. J.; Garcia-Mediavilla, M. V.; Sanchez-Campos, S. and Gonzalez-Gallego, J. (2009) Potential of flavonoids as anti-inflammatory agents: modulation of pro-inflammatory gene expression and signal transduction pathways. Curr. Drug Metab., 10, 256-271.
65. Pinkus, R.; Weiner, L. M. and Daniel, V. (1996) Role of oxidants and antioxidants in the induction of AP-1, NF-kappaB, and glutathione S-transferase gene expression. J. Biol. Chem., 271, 13422-13429.
66. Allen, D. G. and Whitehead, N. P. Duchenne muscular dystrophy-- what causes the increased membrane permeability in skeletal muscle?. Int. J. Biochem. Cell Biol., 43, 290-294.
67. Passaquin, A. C.; Lhote, P. and Ruegg, U. T. (1998) Calcium influx inhibition by steroids and analogs in C2C12 skeletal muscle cells. Br. J. Pharmacol., 124, 1751-1759.
68. Weinblatt, M. E. (1995) Efficacy of methotrexate in rheumatoid arthritis. Br. J. Rheumatol., 34 Suppl 2, 43-48.
69. Callen, J. P. (2000) Dermatomyositis. Lancet, 355, 53-57.
70. Mastaglia, F. L. and Zilko, P. J. (2003) Inflammatory myopathies: how to treat the difficult cases. J. Clin. Neurosci., 10, 99-101.
71. Griggs, R. C.; Moxley, R. T. 3rd; Mendell, J. R.; Fenichel, G. M.; Brooke, M. H.; Pestronk, A.; Miller, J. P.; Cwik, V. A., Pandya, S., Robison, J. & et al. (1993) Duchenne dystrophy: randomized, controlled trial of prednisone (18 months) and azathioprine (12 months). Neurology, 43, 520-527.
72. Kirschner, J.; Schessl, J.; Schara, U.; Reitter, B.; Stettner, G. M.; Hobbiebrunken, E.; Wilichowski, E.; Bernert, G.; Weiss, S.; Stehling, F.; Wiegand, G.; Muller-Felber, W.; Thiele, S.; Grieben, U.; von der Hagen, M.; Lutschg, J.; Schmoor, C.; Ihorst, G. and Korinthenberg, R. (2010) Treatment of Duchenne muscular dystrophy with ciclosporin A: a randomised, double-blind, placebocontrolled multicentre trial Lancet Neurol., 9, 1053-1059.
73. Dalakas, M. C.; Illa, I.; Dambrosia, J. M.; Soueidan, S. A.; Stein, D. P.; Otero, C.; Dinsmore, S. T. and McCrosky, S. (1993) A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N. Engl. J. Med., 329, 1993-2000.
74. Hengstman, G. J.; van den Hoogen, F. H.; Barrera, P.; Netea, M. G.; Pieterse, A.; van de Putte, L. B. and van Engelen, B. G. (2003) Successful treatment of dermatomyositis and polymyositis with anti-tumor-necrosis-factor-alpha: preliminary observations. Eur. Neurol., 50, 10-15.
75. Majmudar, S.; Hall, H. A. and Zimmermann, B. (2009) Treatment of adult inflammatory myositis with rituximab: an emerging therapy for refractory patients. J. Clin. Rheumatol., 15, 338-340.